Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-28
2007-08-28
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C435S002000
Reexamination Certificate
active
10639015
ABSTRACT:
A method of treating tumors and other conditions in a patient is provided. The method involves administering to the patient a treatment medicament. The medicament contains a first component and a second component. The first component can be a quantity of tumor cells derived from the patient, and the second component is a quantity of annexin, preferably annexin V. The first component and second component are provided in a therapeutically effective treatment amount. Other conditions can also be treated with annexin.
REFERENCES:
patent: 5262406 (1993-11-01), Vitale
patent: 195 41 284 (1996-05-01), None
patent: 0 505 817 (1992-09-01), None
patent: WO93/06230 (1993-04-01), None
patent: WO93/11222 (1993-06-01), None
Sestier et al C.R. Acad. Sci. Paris, Sciences de la vie/life Sciences, 1995; 318:1141-1146.
BBA Biochimica et Biophysica Acta, “Okadaic acid increased annexin I and induced differentiation of human promyelocytic leukemia cells”, Eisuke F. Sato, Keisuke Edashige, Masayasu Inoue, Kozo Utsumi, Dec. 1, 1994.
The Anatomical Record, “Lipocortin 1 in Apoptosis: Mammary Regression”, James A. McKanna, Nov. 7, 1994.
The Rockefeller University Press, vol. 182, Nov. 1995, “Early Redistribution of Plasma Membrane Phosphatidylserine Is a General Feature of Apoptosis Regardless of the Initiating Stimulus: Inhibition by Overexpression of Bcl-2 and Ab1”, Seamus J. Martin et al.
Benet et al., pp. 3-32, in The Pharmacological Basis of Therapeutics, Eight ed., McGraw-Hill, Inc., New York, 1990.
Huang et al., FEBS Letters 392:59-62, 1996.
Lima et al., Experientia 30/8:945-946, 1974.
Neurath et al., Virology 204:475-477, 1994.
Tait et al., J. Clin. Lab. Med.:741-748, 1994.
Rabinovich et al., Science, 265:1401-1404, Sep. 1994.
Rice et al., Advances in Pharmacology, 33:389-438, 1995.
Sigma Chemical Company Catalog of Biochemicals and Organic Compounds, pp. 123 and 820-823, 1994.
Nelson et al., pp. 604-626 in Clinical Diagnosis & Laboratory Management by Laboratory Methods, Henry J.B. ed., W.B. Saunders Company, Philadelphia, 1991.
Boas et al., Proceedings of the National Academy of the Sciences 95(6):3077-3081, Mar. 17, 1998.
Bodey et al., Anticancer Research, 20(4):2665-2676, 2000.
Golden, F., p. 44 in Gorman, C., Time, May 18, 1998:37-46.
Gura, T., Science 278:1041-1042, Nov. 1997.
Jain, R.K., Cancer and Metastasis Reviews 9:253-266, 1994.
Bertling Wolf Maximilian
Herrmann Martin
Kalden Joachim Robert
Voll Reinhard
von der Mark Klaus
LandOfFree
Drug, in particular for modulating the immunological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug, in particular for modulating the immunological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug, in particular for modulating the immunological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862432